18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma Journal Article
| Authors: | Port, E. R.; Yeung, H.; Gonen, M.; Liberman, L.; Caravelli, J.; Borgen, P.; Larson, S. |
| Article Title: | 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma |
| Abstract: | Background: The role of positron emission tomography (PET) scanning in determining the extent of disease in patients with breast cancer has not been defined. We investigated the utility of 18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET scanning compared with conventional imaging with computed tomographic scanning and bone scanning in determining the extent of disease in patients with high-risk, operable breast cancer. Methods: This was a prospective study of patients who presented to Memorial Sloan-Kettering Cancer Center for operative treatment of breast cancer. Eighty eligible patients were enrolled and underwent computed tomographic chest, abdomen, pelvis, and bone scans, followed by FDG-PET. Changes in treatment based on scan findings were recorded by the operating surgeons. Imaging findings were verified by biopsy or long-term follow-up. Results: Eight (10%) of 80 patients were found to have metastatic disease that was seen on both conventional imaging and PET. Four additional patients (5%) had additional foci of disease on PET that affected treatment decisions. No patient had findings on conventional imaging alone. Conventional imaging studies resulted in a higher number of findings that generated additional tests and biopsies that ultimately had negative results (17% vs. 5% for PET). There was a statistically significant difference in specificity for PET compared with conventional imaging (P = .01). Conclusions: Conventional imaging and PET were equally sensitive in detecting metastatic disease in patients with high-risk, operable breast cancer, but PET generated fewer false-positive results. FDG-PET scanning should be further studied in this setting and considered in the preoperative evaluation of selected patients with breast cancer. © 2006 The Society of Surgical Oncology, Inc. |
| Keywords: | adult; controlled study; human tissue; treatment outcome; aged; bone neoplasms; middle aged; patient satisfaction; bone tumor; cancer surgery; major clinical study; clinical trial; cancer risk; patient selection; united states; cancer patient; comparative study; positron emission tomography; follow up; cancer diagnosis; diagnostic accuracy; prospective study; sensitivity and specificity; prospective studies; radiopharmaceuticals; medical decision making; metastasis; computer assisted tomography; controlled clinical trial; breast cancer; tomography, x-ray computed; tumor biopsy; diagnostic imaging; breast neoplasms; false negative result; cancer center; statistical significance; diagnostic agent; laboratory test; breast tumor; breast carcinoma; surgeon; fluorodeoxyglucose f 18; medronate technetium tc 99m; computer assisted emission tomography; fluorodeoxyglucose f18; neoplasm metastasis; radiopharmaceutical agent; scintiscanning; intermethod comparison; contrast medium; radiography; thorax radiography; breast surgery; breast biopsy; bone scintiscanning; abdominal radiography; tomography, emission-computed; pelvis radiography; high risk; scintimammography; 18f-2-fluoro-2-deoxy-d-glucose-positron emission tomography; extent of disease |
| Journal Title: | Annals of Surgical Oncology |
| Volume: | 13 |
| Issue: | 5 |
| ISSN: | 1068-9265 |
| Publisher: | Springer |
| Date Published: | 2006-05-01 |
| Start Page: | 677 |
| End Page: | 684 |
| Language: | English |
| DOI: | 10.1245/aso.2006.03.035 |
| PUBMED: | 16538409 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 27" - "Export Date: 4 June 2012" - "CODEN: ASONF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work